---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019380"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:15:12.894998+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences raises $1.2M via warrant exercise with existing accredited investor

## Summary
- Gross proceeds ~$1.2M from exercise of 5,382,500 warrants at reduced price of $0.23/share.
- New warrants issued for 10,765,000 shares (200% coverage) at $0.23, exercisable in 6 months for 5.5 years.
- Exercise price of existing warrants reduced from $0.2503 to $0.23; also reduces price on 6,960,351 unexercised warrants.
- Beneficial ownership limits: 9.99% for existing, 4.99% for new warrants.
- Proceeds earmarked for commercial growth, working capital, and general corporate purposes. Maxim Group acted as agent.

## SEC filing metadata
- accession: 0001558370-23-019380
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/0001558370-23-019380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/rsls-20231121x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019380
- JSON: https://secwatch.observer/filing/0001558370-23-019380.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019380.txt

## Key facts
- Material Agreements
  Vyome Holdings, Inc entered into warrant exercise agreement with an existing accredited investor valued at approximately $1.2 million (effective 2023-11-21).
  - Agreement: equity purchase
  - Counterparty: an existing accredited investor
  - Value: approximately $1.2 million
  - Effective: 2023-11-21
  source text: On November 21, 2023, ReShape Lifesciences Inc. (the “Company”) entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000155837023019380/0001558370-23-019380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.